MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancers
August 24, 2022
August 24, 2022
HOUSTON, Texas, Aug. 24 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Aug. 23, 2022:
* * *
Initial focus of five-year collaboration on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601
* * *
The University of Texas MD Anderson Cancer Center and Erasca, Inc. today announced a strategic research and development collaboration to evaluate multiple agents from . . .
* * *
Initial focus of five-year collaboration on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601
* * *
The University of Texas MD Anderson Cancer Center and Erasca, Inc. today announced a strategic research and development collaboration to evaluate multiple agents from . . .